fda warning compounded semaglutide safety 2024 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Semaglutide Patient Safety Updates |

These experiments reveal the multi-faceted impact of RSL3-mediated inhibition of GPX4 in thyroid cancer cells, by altering DNA damage repair and proliferation signaling pathways, and suppressing thyroid tumor cell growth

Unclear instructions Compounded medications can come with unclear instructions that are hard to follow

Whilst Phase 2 trial results are promising, retatrutide has not yet received MHRA or EMA approval and remains available only within authorised clinical trials

But as these medications have grown in popularity, people have turned to social media to discuss what they call Ozempic vulva or Ozempic vagina a harmless (but sometimes unwelcome) side effect linked to significant weight loss

Our programs are flat-rate with zero hidden fees, no consultation charges, and no dose-change surcharges